PL2797613T3 - Wektory kodujące pręcikowy czynnik żywotności czopków - Google Patents
Wektory kodujące pręcikowy czynnik żywotności czopkówInfo
- Publication number
- PL2797613T3 PL2797613T3 PL12843778T PL12843778T PL2797613T3 PL 2797613 T3 PL2797613 T3 PL 2797613T3 PL 12843778 T PL12843778 T PL 12843778T PL 12843778 T PL12843778 T PL 12843778T PL 2797613 T3 PL2797613 T3 PL 2797613T3
- Authority
- PL
- Poland
- Prior art keywords
- vectors encoding
- viability factor
- cone viability
- derived cone
- encoding rod
- Prior art date
Links
- 101000597428 Homo sapiens Nucleoredoxin-like protein 1 Proteins 0.000 title 1
- 101000597433 Mus musculus Nucleoredoxin-like protein 1 Proteins 0.000 title 1
- 102100035399 Nucleoredoxin-like protein 1 Human genes 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/08—Mydriatics or cycloplegics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161552155P | 2011-10-27 | 2011-10-27 | |
EP12843778.7A EP2797613B1 (en) | 2011-10-27 | 2012-10-26 | Vectors encoding rod-derived cone viability factor |
PCT/US2012/062106 WO2013063383A2 (en) | 2011-10-27 | 2012-10-26 | Vectors encoding rod-derived cone viability factor |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2797613T3 true PL2797613T3 (pl) | 2020-06-15 |
Family
ID=48168788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL12843778T PL2797613T3 (pl) | 2011-10-27 | 2012-10-26 | Wektory kodujące pręcikowy czynnik żywotności czopków |
Country Status (15)
Country | Link |
---|---|
US (2) | US9265813B2 (pl) |
EP (1) | EP2797613B1 (pl) |
JP (1) | JP6293664B2 (pl) |
KR (1) | KR102000141B1 (pl) |
CN (2) | CN104321069A (pl) |
AU (1) | AU2012321102C1 (pl) |
BR (1) | BR112014010091B1 (pl) |
CA (1) | CA2853379C (pl) |
DK (1) | DK2797613T3 (pl) |
ES (1) | ES2774779T3 (pl) |
HK (1) | HK1202049A1 (pl) |
MX (1) | MX354516B (pl) |
PL (1) | PL2797613T3 (pl) |
RU (1) | RU2664673C2 (pl) |
WO (1) | WO2013063383A2 (pl) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2027889A1 (en) * | 2007-06-05 | 2009-02-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New neuronal viability factor and use thereof |
ES2796737T3 (es) * | 2012-10-17 | 2020-11-30 | Inst Nat Sante Rech Med | Métodos y composiciones farmacéuticas para el tratamiento de la degeneración macular relacionada con la edad (AMD) |
CA2942451A1 (en) * | 2014-04-25 | 2015-10-29 | Genethon | Treatment of hyperbilirubinemia |
WO2016185242A1 (en) * | 2015-05-21 | 2016-11-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Synergistic combination of neuronal viability factors and uses thereof |
GB201516066D0 (en) | 2015-09-10 | 2015-10-28 | Young & Co Llp D | Treatment of retinitis pigmentosa |
JP7061067B2 (ja) | 2015-12-14 | 2022-04-27 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | クリグラー・ナジャー症候群の処置のための組成物 |
WO2017120294A1 (en) * | 2016-01-05 | 2017-07-13 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treatment of ocular disorders and blinding diseases |
CN106148528B (zh) * | 2016-07-11 | 2019-10-01 | 赵晨 | 一种遗传性Usher综合征的致病突变及其检测试剂 |
AU2017344059B2 (en) * | 2016-10-11 | 2021-12-23 | Pharma Cinq, Llc | Fusion protein between short form rod-derived cone viability factor and a hydrophilic peptide |
DK3728610T3 (da) * | 2017-12-22 | 2023-08-07 | Sparingvision | Konstrukter omfattende neuronale viabilitetsfaktorer og anvendelser heraf |
CA3088239A1 (en) * | 2018-01-30 | 2019-08-08 | Universiteit Gent | Compositions for use to treat cataract |
CN108504685A (zh) * | 2018-03-27 | 2018-09-07 | 宜明细胞生物科技有限公司 | 一种利用CRISPR/Cas9系统同源重组修复IL-2RG缺陷基因的方法 |
SG11202104295UA (en) * | 2018-11-14 | 2021-06-29 | Regenxbio Inc | Gene therapy for neuronal ceroid lipofuscinoses |
MA54503A (fr) * | 2018-12-19 | 2021-10-27 | Versameb Ag | Arn codant pour une protéine |
US20220332780A1 (en) | 2019-09-10 | 2022-10-20 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
WO2021114662A1 (zh) * | 2019-12-09 | 2021-06-17 | 北京大学第三医院(北京大学第三临床医学院) | CYP4V2和RdCVF在制备药物中的用途 |
CN111733174B (zh) * | 2020-08-07 | 2021-02-09 | 北京大学第三医院(北京大学第三临床医学院) | 一种分离的核酸分子及其用途 |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840293A (en) | 1988-11-16 | 1998-11-24 | Advanced Polymer Systems, Inc. | Ionic beads for controlled release and adsorption |
US5225347A (en) | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
JP4215273B2 (ja) | 1991-04-25 | 2009-01-28 | ブラウン ユニヴァーシティ リサーチ ファンデーション | 選択された治療物質放出用の移植可能で生体適合性の免疫遮断性ビークル |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
US6040172A (en) | 1992-08-14 | 2000-03-21 | The Rockefeller University | Defective DNA viral vector comprising a neural tissue-specific promoter for in vivo expression of a gene |
CA2146747C (en) | 1992-10-09 | 2006-12-19 | Brian A. Naughton | Liver reserve cells |
GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
US5908623A (en) | 1993-08-12 | 1999-06-01 | Cytotherapeutics, Inc. | Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules |
US5552311A (en) | 1993-09-14 | 1996-09-03 | University Of Alabama At Birmingham Research Foundation | Purine nucleoside phosphorylase gene therapy for human malignancy |
TW442569B (en) | 1993-10-25 | 2001-06-23 | Canji Inc | Recombinant adenoviral vector |
CA2176117C (en) | 1993-11-09 | 2006-01-03 | Terence R. Flotte | Generation of high titers of recombinant aav vectors |
US5942496A (en) | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
US5763416A (en) | 1994-02-18 | 1998-06-09 | The Regent Of The University Of Michigan | Gene transfer into bone cells and tissues |
FR2716459B1 (fr) | 1994-02-22 | 1996-05-10 | Univ Paris Curie | Système hôte-vecteur utilisable en thérapie génique. |
WO1995024929A2 (en) | 1994-03-15 | 1995-09-21 | Brown University Research Foundation | Polymeric gene delivery system |
US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
DE69535178T2 (de) | 1994-06-10 | 2006-12-14 | Genvec, Inc. | Adenoviren-vektor systeme und zelllinien |
PT787200E (pt) | 1994-10-28 | 2005-08-31 | Univ Pennsylvania | Adenovirus melhorado e metodos para a sua utilizacao |
US5843742A (en) | 1994-12-16 | 1998-12-01 | Avigen Incorporated | Adeno-associated derived vector systems for gene delivery and integration into target cells |
US5880102A (en) | 1995-01-17 | 1999-03-09 | Duke University | Adenoviral vector system |
US5707618A (en) | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
DE19514541C2 (de) | 1995-04-20 | 1998-01-15 | Daimler Benz Ag | Gaspedal mit Reibkörper |
US5773289A (en) | 1995-06-06 | 1998-06-30 | University Of Pittsburgh | AAV directed targeted integration |
US5869040A (en) | 1995-06-07 | 1999-02-09 | Biogen, Inc | Gene therapy methods and compositions |
US6001650A (en) | 1995-08-03 | 1999-12-14 | Avigen, Inc. | High-efficiency wild-type-free AAV helper functions |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
DE19541450C2 (de) | 1995-11-07 | 1997-10-02 | Gsf Forschungszentrum Umwelt | Genkonstrukt und dessen Verwendung |
US5830727A (en) | 1995-11-18 | 1998-11-03 | Human Gene Therapy Research Institute | Herpes simplex virus amplicon mini-vector gene transfer system |
US20030040467A1 (en) | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
US6299895B1 (en) | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
US6878544B2 (en) | 1996-04-19 | 2005-04-12 | Neurotech Sa | Retinal cell lines with extended life-span and their applications |
US6054142A (en) | 1996-08-01 | 2000-04-25 | Cyto Therapeutics, Inc. | Biocompatible devices with foam scaffolds |
US5994132A (en) | 1996-10-23 | 1999-11-30 | University Of Michigan | Adenovirus vectors |
EP0943003B1 (en) * | 1996-12-02 | 2004-11-17 | Valentis Inc. | Insulin-like growth factor i (igf-i) expression system and methods of use |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
US6303136B1 (en) | 1998-04-13 | 2001-10-16 | Neurotech S.A. | Cells or tissue attached to a non-degradable filamentous matrix encapsulated by a semi-permeable membrane |
US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
US5994134A (en) | 1998-05-04 | 1999-11-30 | Canji, Inc. | Viral production process |
EP0974660A1 (en) | 1998-06-19 | 2000-01-26 | Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) | Newcastle disease virus infectious clones, vaccines and diagnostic assays |
US6544785B1 (en) | 1998-09-14 | 2003-04-08 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA viruses |
US6146642A (en) | 1998-09-14 | 2000-11-14 | Mount Sinai School Of Medicine, Of The City University Of New York | Recombinant new castle disease virus RNA expression systems and vaccines |
US6759237B1 (en) | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
US6303362B1 (en) | 1998-11-19 | 2001-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Adenoviral vector and methods for making and using the same |
US6361771B1 (en) | 1999-04-06 | 2002-03-26 | Neurotech S.A. | ARPE-19 as a platform cell line for encapsulated cell-based delivery |
US6864085B2 (en) | 1999-12-14 | 2005-03-08 | Novartis Ag | Bovine immunodeficiency virus (BIV) based vectors |
US7098030B2 (en) | 1999-12-31 | 2006-08-29 | Mirus Bio Corporation | Polyampholytes for delivering polyions to a cell |
IL140844A0 (en) | 2001-01-10 | 2002-02-10 | Polygene Ltd | Cationic polysaccharide compositions |
FR2823221B1 (fr) * | 2001-04-06 | 2004-04-02 | Univ Pasteur | Sequences associees a la degenerescence retinienne et applications |
AU2002360291A1 (en) | 2001-12-17 | 2003-06-30 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences |
JP2005533485A (ja) * | 2002-02-04 | 2005-11-10 | ノバルティス アクチエンゲゼルシャフト | 組換えウシ免疫不全ウイルスに基づく遺伝子導入システム |
DK1542536T3 (da) | 2002-07-25 | 2012-01-23 | Scripps Research Inst | Hæmatopoietiske stamceller og fremgangsmåder til behandling af neovaskulære øjensygdomme dermed |
DE10260805A1 (de) * | 2002-12-23 | 2004-07-22 | Geneart Gmbh | Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins |
KR20060056420A (ko) * | 2003-05-02 | 2006-05-24 | 더 스크립스 리서치 인스티튜트 | 조혈 줄기세포 및 이를 사용한 신생혈관 안구 질환의치료방법 |
FR2870241B1 (fr) | 2004-05-13 | 2015-02-27 | Novartis Ag | Facteur de viabilite des cones derive des batonnets ou rdcvf et applications |
US9265814B2 (en) | 2005-12-30 | 2016-02-23 | Neurotech Usa, Inc. | Micronized device for the delivery of biologically active molecules and methods of use thereof |
NZ578873A (en) | 2007-03-01 | 2012-01-12 | Wellstat Ophthalmics Corp | Complement factor B analogs and uses for the treatment of complement mediated disease such as inflammation |
EP2027889A1 (en) * | 2007-06-05 | 2009-02-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New neuronal viability factor and use thereof |
WO2009071659A1 (en) * | 2007-12-06 | 2009-06-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Trophic factor for the treatment of retinal degenerative diseases |
WO2009146183A1 (en) * | 2008-04-15 | 2009-12-03 | Genzyme Corporation | Methods to produce rod-derived cone viability factor (rdcvf) |
WO2009134681A2 (en) | 2008-04-30 | 2009-11-05 | The Trustees Of The University Of Pennsylvania | Aav7 viral vectors for targeted delivery of rpe cells |
JP5748223B2 (ja) | 2008-09-10 | 2015-07-15 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ニューロン生存因子およびその使用 |
CN102272302B (zh) * | 2008-10-31 | 2015-04-15 | 生物载体株式会社 | 增强重组蛋白表达的方法 |
DE102009016934A1 (de) | 2009-04-08 | 2010-10-14 | Daimler Ag | Brennstoffzelle, Brennstoffzellenstapel und Verfahren zum Abdichten einer Brennstoffzelle |
EP2486128A4 (en) | 2009-10-08 | 2013-10-09 | Neurotech Usa Inc | USE OF THE PEDF IN AN ENCAPSULATED CELL DELIVERY SYSTEM |
-
2012
- 2012-10-26 AU AU2012321102A patent/AU2012321102C1/en active Active
- 2012-10-26 CA CA2853379A patent/CA2853379C/en active Active
- 2012-10-26 PL PL12843778T patent/PL2797613T3/pl unknown
- 2012-10-26 CN CN201280064474.1A patent/CN104321069A/zh active Pending
- 2012-10-26 DK DK12843778.7T patent/DK2797613T3/da active
- 2012-10-26 KR KR1020147011857A patent/KR102000141B1/ko active IP Right Grant
- 2012-10-26 ES ES12843778T patent/ES2774779T3/es active Active
- 2012-10-26 US US14/354,415 patent/US9265813B2/en active Active
- 2012-10-26 BR BR112014010091-8A patent/BR112014010091B1/pt active IP Right Grant
- 2012-10-26 JP JP2014539038A patent/JP6293664B2/ja not_active Expired - Fee Related
- 2012-10-26 CN CN201911125836.3A patent/CN110777124A/zh active Pending
- 2012-10-26 EP EP12843778.7A patent/EP2797613B1/en active Active
- 2012-10-26 MX MX2014004949A patent/MX354516B/es active IP Right Grant
- 2012-10-26 RU RU2014121256A patent/RU2664673C2/ru active
- 2012-10-26 WO PCT/US2012/062106 patent/WO2013063383A2/en active Application Filing
-
2015
- 2015-03-10 HK HK15102471.7A patent/HK1202049A1/xx unknown
- 2015-12-08 US US14/962,337 patent/US10040835B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10040835B2 (en) | 2018-08-07 |
WO2013063383A2 (en) | 2013-05-02 |
US20160108099A1 (en) | 2016-04-21 |
JP2015501156A (ja) | 2015-01-15 |
MX354516B (es) | 2018-03-08 |
CN104321069A (zh) | 2015-01-28 |
US9265813B2 (en) | 2016-02-23 |
EP2797613A4 (en) | 2015-09-09 |
RU2664673C2 (ru) | 2018-08-21 |
CA2853379A1 (en) | 2013-05-02 |
AU2012321102C1 (en) | 2016-11-10 |
BR112014010091A2 (pt) | 2020-10-27 |
ES2774779T3 (es) | 2020-07-22 |
EP2797613A2 (en) | 2014-11-05 |
CN110777124A (zh) | 2020-02-11 |
BR112014010091B1 (pt) | 2022-11-08 |
KR102000141B1 (ko) | 2019-07-15 |
AU2012321102B2 (en) | 2016-07-14 |
DK2797613T3 (da) | 2020-03-02 |
MX2014004949A (es) | 2014-09-12 |
KR20140092320A (ko) | 2014-07-23 |
AU2012321102A1 (en) | 2013-05-16 |
WO2013063383A3 (en) | 2013-06-20 |
JP6293664B2 (ja) | 2018-03-14 |
CA2853379C (en) | 2020-11-24 |
HK1202049A1 (en) | 2015-09-18 |
RU2014121256A (ru) | 2015-12-10 |
US20140328821A1 (en) | 2014-11-06 |
EP2797613B1 (en) | 2019-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1202049A1 (en) | Vectors encoding rod-derived cone viability factor | |
GB2501836B (en) | Video encoding | |
DK3505720T3 (en) | Cementering under styret tryk | |
PL2914359T3 (pl) | Separator magnetyczny | |
GB201108879D0 (en) | Vector | |
EP2721506A4 (en) | RECONCILIATION OF EFFECTIVE STATUS | |
GB2501958B (en) | Backpack | |
HK1171995A1 (en) | Free cart | |
GB2492645B8 (en) | Cryostat | |
EP2765242A4 (en) | CONSTRUCTION MACHINE | |
EP2729605A4 (en) | RNA YY1 INTERACTIONS | |
PL2771471T3 (pl) | Konstrukt | |
EP2662268A4 (en) | CAP MOUNTING STRUCTURE | |
ZA201400624B (en) | Solids-handling equipment | |
ZA201308491B (en) | Solids-handling equipment | |
PL2831757T3 (pl) | Wektorowy kwantyzator | |
PL2584028T3 (pl) | Cząstka | |
EP2873074A4 (en) | VECTORIAL QUANTIFICATION | |
GB201317652D0 (en) | Magnetic separator | |
GB201114045D0 (en) | Magnet | |
GB2490514B (en) | Case structure | |
HK1150357A2 (en) | Synsepalum duleificum tea | |
GB201109834D0 (en) | Rucksack | |
GB201114452D0 (en) | Paca | |
GB201115328D0 (en) | Foc |